Background: Transducin β-like 1 X-linked receptor 1 (TBL1XR1) is an important transcriptional cofactor involved in the regulation of many signaling pathways, and is associated with carcinogenesis and tumor progression. However, the precise role of TBL1XR1 in these processes is not well understood. Methods: We detected the expression of TBL1XR1 protein and mRNA in nasopharyngeal carcinoma (NPC) cell lines and biopsies by western blotting, real-time PCR and immunohistochemical staining (IHC). Overexpression of TBL1XR1 in NPC enhanced chemoresistance to cisplatin using two NPC cell lines in vitro and in vivo.
Background
Nasopharyngeal carcinoma (NPC) is a common malignant carcinoma of the head and neck region, and is more prevalent in regions of Southeast Asia and Africa than elsewhere [1] . The etiological factors of NPC mainly consist of genetic susceptibility, Epstein-Barr virus (EBV) infection and environmental factors [1] . Currently, the standard treatment for NPC consists of radiotherapy and adjuvant cisplatin chemotherapy. Although this therapeutic regimen results in a high cure rate, a considerable number of patients suffer from therapeutic resistance, distant metastases and local recurrence after treatment [2] [3] [4] [5] [6] . Thus, it is important to understand the molecular events involved in the development and progression of NPC, with an aim to explore effective strategies that can enhance the sensitivity of tumor cells to drug-induced apoptosis.
Transducin β-like 1 X-linked receptor 1 (TBL1XR1) or transducin β-like-related protein 1 (TBLR1) was originally identified as a component of the nuclear receptor corepressor (N-CoR) complex [7] . TBL1XR1 is high homology to Transducin β-like protein 1 (TBL1); both contain F-box/ WD-40 repeats that are required for binding to the silencing mediator for retinoid and thyroid hormone receptors (SMRT) and the N-CoR corepressor complex, which mediates transcriptional repression by unliganded nuclear receptors [8, 9] . TBL1XR1 also function as an E3 ubiquitin ligase that recruits UbcH5 ubiquitin conjugating enzymes/19S proteasome, and subsequently replaces of corepressors with coactivators in a ligand-dependent manner [10] . Previous studies have established TBL1XR1 as a key player in the regulation of multiple signaling pathways (Wnt/β-catenin, Notch, NF-κB, and nuclear receptor) and gene transcription [10] [11] [12] [13] . In addition, TBL1XR1 has been found to affect carcinogenesis and tumor progression. Liu et al. showed that TBL1XR1 is overexpressed in lung cancer cells, and particularly in a human immortalized bronchial epithelial cell line, indicating that the abnormal expression of TBL1XR1 might be an early event during lung cancer development [14] . Kadota and colleagues observed that TBL1XR1 levels are amplified in breast cancer, and the protein plays an oncogenic role in breast cancer progression [15] . Furthermore, the hepatic transcriptional cofactor, TBL1/TBLR1, was found to regulate liver lipid metabolism via the nuclear receptor peroxisome proliferator-activated receptor (PPAR)α, and the deficiency of TBL1/TBLR1 activity induced liver steatosis and hypertriglyceridemia [16] .
In this study, we showed that TBL1XR1 is upregulated in NPC cell lines and clinical samples, and TBL1XR1 expression levels were correlated with the clinicopathologic characteristics of NPC patients. Furthermore, TBL1XR1 induced anti-apoptotic abilities in NPC cells by activating NF-κB signaling pathway. Our data indicated that TBL1XR1 is a novel prognostic factor and may serves as an effective biomarker for selective therapeutic regimen for NPC patients.
Results

Up-regulation of TBL1XR1 in NPC cells
Western blot analysis showed that TBL1XR1 was highly expressed in all nine NPC cell lines, whereas it was weakly detected in normal nasopharyngeal epithelial cells (NPECs; Figure 1A ). Reverse transcription (RT)-PCR and real-time PCR were performed to detect and measure expression levels of TBL1XR1 mRNA. All nine NPC cell lines showed significantly higher levels of TBL1XR1 mRNA compared to NPECs ( Figure 1B ). This was consistent with the high levels of TBL1XR1 protein measured in NPC cells.
To validate whether the upregulation of TBL1XR1 in NPC cell lines was clinically relevant, we also examined protein and mRNA levels in NPC tissues.TBL1XR1 was found to be overexpressed to varying degrees in all 10 NPC samples ( Figure 1C ), and was barely detectable in the three healthy nasopharyngeal epithelial tissue samples. RT-PCR and real-time PCR revealed that TBL1XR1 mRNA was upregulated in tumor samples ( Figure 1D ), confirming that TBL1XR1 is overexpressed in NPC patients.
TBL1XR1 expression correlates with clinicopathologic characteristics of NPC patients
To further demonstrate TBL1XR1 protein is overexpressed in clinical samples of NPC, we performed immunohistochemical (IHC) staining on paraffin-embedded archived biopsies (105 NPC samples and 3 normal nasopharyngeal epithelial tissue samples). In agreement with the results above, TBL1XR1 was barely detected in normal nasopharyngeal epithelial tissues, while strong expression was observed in the tumor cells of NPC samples (Figure 2A ). TBL1XR1 was detectable in 94 of 105 (89.52%), and high levels of expression were observed in 52 (49.52%) of the samples (Table 1 ).
We also investigated the possible correlations between TBL1XR1 expression levels and the clinicopathologic characteristics of NPC. Analysis of 105 NPC samples indicated that TBL1XR1 expression was correlated with clinical staging (P = 0.001), T classification (P = 0.040), N classification (P = 0.003), and patient survival (P = 0.001). These results show that the observed correlation between TBL1XR1 expression and NPC progression is clinically relevant.
Five-year survival rate in NPC patients
The results of the Kaplan-Meier survival analysis and logrank tests demonstrated that high expression of TBL1XR1 was correlated with poor prognosis in NPC patients (P = 0.008 vs. low TBL1XR1 expression, Figure 2B ). The five-year overall survival rate of the group that expressed low levels of TBL1XR1 was 78.939% (95% CI: 88.935%-62.153%) compared to 59.183% (95% CI: 71.667%-44.758%) for the group expressing high levels. Multivariate Cox regression analysis indicated that TBL1XR1 was an independent prognostic factor for overall survival in NPC (Table 2) , and may therefore act as a prognostic biomarker.
Increased TBL1XR1 expression suppresses cisplatin-induced apoptosis
To investigate the biological effect of TBL1XR1 in NPC progression, two NPC cell lines (SUNE1 and CNE2) were established that stably overexpressed TBL1XR1 ( Figure 3A ). Cells were treated with increased doses of cisplatin, a commonly used chemotherapeutic agent. The proportion of cells still alive after treatment was plotted on a survival curve. Following cisplatin treatment, control cells exhibit a marked decline in survival rate, while the decline in survival of cells that overexpressed TBL1XR1 was much reduced ( Figure 3B ). The results of TUNEL and Annexin-V binding assays suggested that both TBL1XR1-overexpressing cell lines exhibited enhanced resistance to cisplatin treatment ( Figure 3C and D). Taken together, these data indicated that ectopic overexpression of TBL1XR1 could reduce the effectiveness of cisplatin against NPC cells.
TBL1XR1 knockdown increases sensitivity to cisplatin-induced apoptosis
In order to investigate the role of TBL1XR1 in apoptotic pathways, TBL1XR1 expression was silenced using specific shRNAs ( Figure 4A ). As expected, TBL1XR1 downregulated cells were more sensitive to cisplatin than control cells; survival curves were steeper ( Figure 4B ), and the quantity of viable and non-viable apoptotic cells increased ( Figure 4C and D, respectively). In summary, TBL1XR1 played an important role in resistance to cisplatin treatment in NPC cells.
TBL1XR1 suppressed the sensitivity of NPC cells to cisplatin in vivo
To examined the effect of TBL1XR1 on apoptosis in vivo, nude mice were subcutaneously injected with CNE2 cells. When tumors reached a volume of about 100 mm 3 , animals were randomly assigned to two groups and given an intraperitoneal injection of 100 ml DMSO (control) or cisplatin. Interestingly, the volumes and weights of tumors formed by the CNE2-TBL1XR1 cells were not significantly affected by cisplatin treatment (Figure 5A -C). However, tumors formed by vector control cells, or by cells with depleted endogenous TBL1XR1, exhibited a striking inhibition of tumor growth in terms of both tumor volume and weight after cisplatin treatment ( Figure 5A -C). These results are strongly indicative of TBL1XR1-associated resistance to cisplatin, and are consistent with the other results.
To determine whether high TBL1XR1-expression alters cell survival within tumors, we analyzed tumors harvested from animals in indicated groups for apoptotic frequency. As shown in Figure 5D , consistent with above results, after cisplatin treatment, the percentage of apoptotic cells in tumors obtained from the CNE2-TBL1XR1 group was significantly reduced in comparison with that in tumors obtained from the other group, strongly suggesting a suppressive effect of elevated TBL1XR1 on cisplatin sensitivity within the NPC cells.
TBL1XR1 activates NF-κB signaling pathway
TBL1XR1 is involved in multiple pathways, including the Wnt/β-catenin, Notch, NF-κB, and nuclear receptor pathways [10] [11] [12] [13] , The activation of NF-κB signaling is associated with anti-apoptotic properties, and we investigated whether TBL1XR1 promoted anti-apoptotic effects in NPC cells via this pathway. The NF-κB luciferase assay revealed that TBL1XR1 overexpression was accompanied by the downregulation of NF-κB and genes downstream of NF-κB ( Figure 6A and B).
To establish the clinical relevance of this observation, TBL1XR1 expression and NF-κB activation was measured in 10 freshly collected clinical NPC samples. Real-time RT-PCR, Western blot and EMSA assays showed that TBL1XR1 protein levels were positively correlated with mRNA levels of several NF-κB downstream target genes, and also with NF-κB DNA binding. TBL1XR1 is upregulated in NPCs, activates the NF-κB signaling pathway and confers anti-apoptotic properties on these cells.
Moreover, when we further examined the effect of the Epstein-Barr virus latent membrane protein 1 (LMP1) on the expression levels of TBL1XR1 in SUNE1, CNE2 and C666 NPC cells. Our result showed that neither overexpressing nor silencing LMP1 had any influence on the mRNA and protein levels of TBL1XR1 (Additional file 1: Figure S1 ), implicating that the biological role of TBL1XR1 in NPC cells herein was EBV-independent. 
Discussion
The key finding in this report lies in, for the first time, the biological role of TBL1XR1 in NPC progression and chemotherapy resistance. TBL1XR1 mRNA and protein levels were both elevated in NPC cells in vitro, and this was also observed in clinical samples. In addition, in vitro assays indicated that TBL1XR1 promoted antiapoptosis in NPC cells by activating NF-κB pathway, further cementing the role of TBL1XR1 as an oncogenic protein [14, 15] . Local recurrence and therapy resistance are the two main problems associated with the treatment of NPC patients. In this study, NPC cells were treated with cisplatin, a standard chemotherapeutic agent that can also enhance the effectiveness of radiotherapy when used in combination with others. The MTT, TUNEL and Annexin-V binding assays all showed that elevated TBL1XR1 expression markedly reduced the ability of cisplatin to kill NPC cells. Conversely, cells in which TBL1XR1 was downregulated were more sensitive to cisplatin.
The above results led us to believe that upregulation of TBL1XR1 may reduce cisplatin-induced apoptosis in NPC cells. Aberrant apoptotic signals is significantly involved in oncogenesis and tumor regression in numerous cancers, including NPC. Previous researchers have identified several factors associated with apoptosis. B-cell lymphoma 2 (Bcl-2), a classical anti-apoptosis protein, has been shown to be overexpressed in biopsy specimens from NPC patients, and Bcl-2 is predominately co-expressed with p53 in NPC [17] [18] [19] [20] . The apoptotic inhibitor, survivin, has been found to be upregulated in NPC, and may serve as a potential prognostic marker for NPC patients [21] [22] [23] . Other molecules have also been reported to be correlated with the protection of NPC cells from apoptosis [24] [25] [26] [27] [28] [29] . However, the exact mechanisms underlying the regulation of apoptosis in NPC need to be explored conclusively.
NF-κB signaling plays an vital role in cell survival by upregulating gene products that block apoptosis. TBL1XR1, a corepressor/coactivator exchange factor, has been reported to regulate switch between gene repression and gene activation in transcriptional regulation, and be involved in activation of mutiple signalling pathways, including NF-κB pathways [10] . Hoberg et al. proposed that TBL1XR1 function as an E3 ubiquitin ligase that recruits UbcH5 ubiquitin conjugating enzymes, and Ubc5-dependent targeting to the proteasome and removes SMRT from NF-κB binding region, subsequently replaces of SMRT with coactivators in a ligand-dependent manner [6] . Above studies suggested us that upregulation of TBL1XR1 in NPC, may promote resistance to cisplatin-induced apoptosis via stimulating the NF-κB pathway. The results of the NF-κB luciferase reporter assay demonstrated that TBL1XR1 was indeed involved. In addition, real-time RT-PCR results indicated that there was a strong positive correlation between the expression of NF-κB target genes and TBL1XR1 expression level in two independent NPC cell lines. This relationship held true in ten freshly collected clinical NPC samples, which emphasized the clinical relevance of our findings.
TBL1XR1 is located at 3q26.32. Though the chromosome region 3q21-q26.2 was previously reported to be frequently amplified in NPC tissues [30, 31] . By using the genomic PCR assay, we did not find a significant change of TBL1XR1 copy number in NPC tissues (Additional file 2: Figure S2 ), indicating that TBL1XR1 overexpression is not due to the genomic amplification. Interestingly, our results indicated that TBL1XR1 was expressed at a very low level in normal samples, but markedly in NPC samples. Moverover, TBL1XR1 mRNA and protein expression are significantly correlated, suggeting that TBL1XR1 might be upregulated at the transcriptional level. By analysis of the promoter region of TBL1XR1 using the CONSITE program, we found two typical responsive E-BOX elements of transcriptional factor c-myc, which has been reported to be overexpressed in NPC [32] . Meanwhile, CpG islands were also observed in TBL1XR1 promoter. Thus, it would be of great interest to further investigate whether upregulation of TBL1XR1 in NPC is attributed to c-myc transactivation or demethylation of CpG islands in NPC samples.
Conclusion
In summary, this study has established clear links between the transcription cofactor TBL1XR1 and both NPC progression and chemotherapy resistance. Nevertheless, understanding the precise role of TBL1XR1 in the progression of NPC and activation of the NF-κB signaling will not only advance our knowledge of the mechanisms underlying NPC progression, but also help establish TBL1XR1 as a biomarker for clinical outcome and a potential therapeutic target in NPC.
Materials and methods
Cell lines
The normal nasopharyngeal epithelial cell line was cultured at 37°C and 5%CO 2 with keratinocyte serum-free medium (Invitrogen, Carlsbad, CA) supplemented with epithelial growth factor, bovine pituitary extract, 120 μg/ml streptomycin and 120 μg/ml penicillin [33] . The human NPC cell lines, including C666, CNE1, CNE2, SUNE1, Hone1, HNE1, HK1, 5-8 F and 6-10B were grown in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (HyClone, Logan, UT) and 100 μg/μL streptomycin, and 100 μg/μL penicillin in a humidified incubator containing 5% CO 2 at 37°C.
Patient information and tissue specimens
This study was conducted on a total of 105 paraffinembedded NPC samples, which were histopathologically and clinically-diagnosed NPC patients treated at the Cancer Center, Sun Yat-sen University between April 2000 and January 2003. All 105 cases of NPC were undifferentiated non-keratinizing carcinoma with World Health Organization (WHO) type III pathology. The normal nasopharyngeal epithelial tissues were obtained from three patients undergoing nasopharyngeal mucosal biopsies, who were subsequently diagnosed with chronic inflammation of nasopharyngeal mucosa. For the use of these clinical materials for research purposes, prior patient consent and approval from the Ethics Committees of the Cancer Center, Sun Yat-sen University in advance of the study.
Plasmids and transfections
pMSCV/TBL1XR1-overexpressing human TBL1XR1 was generated by subcloning the PCR-amplified human TBL1XR1 coding sequence into pMSCV vector. To silence endogenous TBL1XR1, two TBL1XR1 small hairpin RNA (shRNA)s were designed and cloned into the pSuper-retropuro vector to generate pSuper-retro-TBL1XR1-RNAis, respectively [34] . Retroviral production and infection were performed as described previously [34] . Stable cell linesexpressing TBL1XR1 or TBL1XR1 RNAis were passaged and harvested after selection for 10 days with 0.5 μg/ml puromycin medium.
RNA extraction, reverse transcription, and real-time PCR
Total RNA from cultured cells and fresh tissues were extracted using the Trizol reagent (Invitrogen) according to the manufacturer's instruction. The extracted RNA was pretreated with RNase-free DNase, and about 2ug RNA from each sample was used for cDNA synthesis with iScriptcDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). Real-time PCR primes were designed using the Primer Express Software Version 2.0 and the primer sequences are: TBL1XR1 forward primer: GAATTTCCT TGTGCCTCCAT; TBL1XR1 reverse primer: TGCAACT GAATATCCGGTCA; Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward prime: 5′-GACTCAT GACCACAGTCC ATGC-3′; GAPDH reverse primer: 5′-AGAGGCA GGGATGATGTTCTG-3′. Expression data were normalized to the geometric mean of housekeeping gene GAPDH to control the variability in expression levels and calculated as 2 -[(Ct of TBL1XR1) -(Ct of GAPDH)] , where C t represents the threshold cycle for each transcript.
Western blotting
Western blot analysis was performed according to standard methods as described previously [34] , using anti-TBL1XR1 rabbit polyclonal antibody (1:3,000; Sigma). Blot membranes were stripped and reprobed with anti-GAPDH antibody (1:1,000; Sigma) as a loading control.
Immunohistochemistry
Immunohistochemistry staining was carried out using Histostain-Plus Kits (Invitrogen) following the manufacturer's protocols. Two independent pathologists blinded to the clinical parameters conducted the staining index (SI) for TBL1XR1 expression. The staining results were scored based on the following criteria: (i) percentage of positive tumor cells in the tumor tissue: 0 (0%), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%) and 4 (76%-100%); (ii) staining intensity: 0 (no staining), 1 (weak staining = light yellow), 2 (moderate staining = yellow brown), and 3 (strong staining = brown). The SI was calculated as staining intensity score × proportion of positive tumor cells (range from 0 to 12) [34] . An optimal cutoff value was identified: the SI > 6 was used to define as TBL1XR1 high expression while SI ≤ 6 as TBL1XR1 low expression.
MTT assay 5,000 cells were seeded in triplicate in 96-well plates, All cells were incubation with Cisplatin (Hospira Australia Pty Ltd., 5 μg/ml, 10 μg/ml, 15 μg/ml, 20 μg/ml) for 48 hours. 20 μl of 5 mg/ml MTT was added 4 hours prior to the time points when 150 ml of DMSO was added for each well. The absorbance was measured at 490 nm. All experiments were performed in triplicates.
TUNEL assay
The DeadEndTM Fluorometric TUNEL System (Promega, Madison, WI) was used for TUNEL assay according to the manufacturer's instruction. 3 × 10 4 cells were seeded on coverslips (Fisher Scientific) in 24-well plates. After 24 hours, all cells were incubation with Cisplatin, followed by washed once with cold PBS followed by fixation in freshly prepared 4% formaldehyde solution in PBS (pH 7.4) for 25 min at 4°C. The fixed slides were washed with PBS for 5 min and then permeabilized with 0.2% Triton X-100 solution in PBS for 5 min. After a 5-min rinse with PBS, and cells were covered with 100 μL Equilibration Buffer for 5 min, followed by a 60-min incubation with 2 x SSC at 37°C to terminate the reaction and a 5 min PBS wash. The samples were then stained in the dark with 1 μg/ml propidium iodide (PI) solution for 15 min. After a final wash with H 2 O for 5 min at ambient temperature and air-dry, samples were immediately analyzed under a fluorescence microscope using a standard fluorescein filter set to view the green fluorescence of fluorescein at 520 nm, the red fluorescence of PI at 620 nm.
Annexin-V binding assay
The ApopNexinTM FITC Apoptosis Detection Kit (Millipore, Lake Placid, NY) was used to examine the apoptotic cells according to manufacturer's instruction. 3 × 10 5 cells were seeded in triplicate in 6-well plates. After 24 hours, all cells were incubation with Cisplatin, followed by washes with PBS and then with an Annexin-V binding solution. Subsequently, 150 μl of an Annexin-V antibody in Binding Buffer was added to each culture well and incubated for 15 min, followed by addition of 1.5 μL of PI at 1 mg/ml and a further incubation for 5 min. 10,000 cells were analyzed on a flow cytometer (FACSCalibur; BD Biosciences).
Luciferase assay
3 × 10 4 cells were seeded in triplicate in 24-well plates. After 24 h, 500 ng NF-κB luciferase reporter plasmids plus 5 ng of pRL-TK renilla plasmid (Promega) were cotransfected into NPC cells using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's recommendation. Luciferase and renilla signals were measured 48 h after transfection using the Dual Luciferase Reporter Assay Kit (Promega) according to a protocol provided by the manufacturer. Three independent experiments were performed, and the data are presented as mean ± SD.
Electrophoretic Mobility Shift Assay (EMSA)
Briefly, the nuclear proteins were harvested from fresh NPC biopsies using the NE-PER Nuclear protein extraction kit (Pierce Biotechnology) according to the manufacturer's instructions. The NF-κB binding probe was synthesized with 5′ biotin labels. Binding reactions were equivalent in that 20 fmol probe was incubated with 5.0 μg nuclear proteins, and then subjected to non-denaturing polyacrylamide gel electrophoresis. The NF-κB-DNA-binding complex shift was then dected using the LightShift Chemiluminescent EMSA Kit (Pierce Biotechnology). Oct-1-DNA-binding complexes served as a loading control. The DNA probes used were as following: NF-κB: sense, 5′-AGTTGAGGGGACTTTCCCAGGC-3′, antisense, 5′-GCCTGGG AAAGTCCCCTCAAC-3′; OCT-1: sense, 5′-TGTCGAATGCAAATCACTAGAA-3′, antisense, 5′-TTCTAGTGATTTGCATTCGACA-3′.
In vivo experiment
Female BALB/c nude mice (4-5 weeks of age, 18-20 g) were purchased from the Animal Center of Guangdong Province and were housed in barrier facilities on a 12hour light/dark cycle. All experiments were approved by the animal care committee at the Sun Yat-sen University Cancer Center. The BALB/c nude mice were randomly divided into 2 groups (12/group). One group of mice were inoculated subcutaneously with CNE2-TBL1XR1/ CNE2-Vector cells (1 × 10 6 suspended in 100 mL sterile PBS) per mouse, another group of mice inoculated with CNE2-Ri-Vector /CNE2-TBL1XR1-Ri2 cells (1 × 10 6 suspended in 100 mL sterile PBS) per mouse. Tumor volume was calculated using the equation (LxW 2 )/2. Mice were checked every 2 days for xenograft development. When tumors became palpable (about 100 mm 3 ), each group of mice mice were randomly divided into 2 subgroups (6/group), followed by intraperitoneal injection of 100 mL vehicle (dimethyl sulfoxide, DMSO), Cisplatin (5 mg/kg), respectively, every2 days.
Statistical analysis
All statistical analyses were carried out using the SPSS v.13.0 statistical software packages (SPSS Inc, Chicago, IL, USA). The correlation between TBL1XR1 expression and the clinicopathological characteristics was analyzed by the Chi-Square test. Survival curves were plotted by the Kaplan-Meier method and compared with the logrank test. The differences between experimental conditions were compared using Student's t tests. P ≤ 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1 . TBL1XR1 expression is independent of LMP1. (A) Overexpression of LMP1 in SUNE1 and CNE2 cell lines. Western blotting analysis of TBL1XR in SUNE1-vector, SNUE-LMP1, CNE2-vector and CNE2-LMP1 cells. GAPDH was used as loading control. (B) LMP1 knockdown was achieved by introducing specific shRNA in C666 cell line. (C) Real-time PCR analysis of TBL1XR in SUNE1-vector, SNUE-LMP1, CNE2-vector, CNE2-LMP1, C666-vector and C666-LMP1-Ri cells. TBL1XR1 expression levels are presented as fold changes relative to vector-control cells and normalized to GAPDH. * P ≤ 0.05.
Additional file 2: Figure S2 . The copy number of the TBL1XR1 gene was measured by a TaqMan Copy Number Assay. RPPH1 gene on chromosome 14 as a reference locus.
Abbreviations TBL1XR1: Transducin β-like 1 X-linked receptor 1; NPC: Nasopharyngeal carcinoma; IHC: Immunohistochemical staining; TBLR1: Transducin β-like-related protein 1; TBL1: Transducin β-like protein 1; N-CoR: Nuclear receptor corepressor; SMRT: Silencing mediator for retinoid and thyroid hormone receptors; PPAR: Peroxisome proliferator-activated receptor; CGH: Comparative genomic hybridization; shRNA: Small hairpin RNA.
